In Conversation: What do we know about the gut microbiome in IBD?
32m
·
In Conversation
·
Inflammatory bowel disease (IBD) — an umbrella term for conditions including Crohn’s disease and ulcerative colitis — affects millions of people worldwide, sometimes severely affecting their quality of life. How is the gut microbiome of a person with IBD different, and can we use diet to change it and help with disease management? To answer these and other questions, we are in conversation withDr. Marcel de Zoete, associate professor in the Department of Medical Microbiology at UMC Utrecht in The Netherlands, who has studied the gut microbiome in IBD. Also joining us is Zosia Krajewska, who lives with IBD after receiving a diagnosis at age 14.
The episode In Conversation: What do we know about the gut microbiome in IBD? from the podcast In Conversation has a duration of
32:13. It was first published
More episodes from In Conversation
In Conversation: Is intermittent fasting actually bad for your heart?
This episode of our podcast takes a deep dive into intermittent fasting and its effects on health. Joining the conversation is Ali Javaheri, MD, PhD, assistant professor of medicine from the Center for Cardiovascular Research at Washington University. Dr Javaheri explains what intermittent fasting does to the body and discusses the benefits and dangers of this eating plan in light of a recent viral study that found 8-hour time-restricted eating may relate to a higher risk of cardiovascular death. In Conversation is a Healthline Media original podcast. This episode was produced by Flamingo Media for Medical News Today.
In Conversation: What do we know about the weight loss plateau on Wegovy?
In this episode of our podcast, we take a deep dive into the topic of semaglutide — or GLP-1 receptor agonist drugs — use for weight loss. How does semaglutide help with weight management, why do some people on Wegovy hit a weight loss plateau, and what are some issues to keep in mind when it comes to using semaglutide for weight loss? Dr. Simon Cork, senior lecturer in the Faculty of Health, Medicine and Social Care at Anglia Ruskin University in the United Kingdom helps us answer these and more questions.
2023 in medicine: Artificial sweeteners, colon cancer, and male birth control
In our wrap-up of 2023’s most pressing and perhaps controversial research in the health and wellness field, Medical News Today’s editors — Andrea Rice, Maria Cohut, and Yasemin Nicola Sakay — delve into three interesting topics: The WHO’s decision to declare sucralose a potential carcinogen, the symptoms of colon cancer and the worrying rise of cases in young people, and the still-elusive male birth control pill.
In Conversation: Why exercise is key to living a long and healthy life
How do we prolong our longevity? Plenty of recent evidence suggests that exercise — in the correct amount and combination — can help us live longer, healthier lives. This episode of our podcast discusses how and why intentional physical activity prolongs our health span. Joining the conversation isDr. Borja del Pozo Cruz, principal researcher in Applied Health Sciences at the University of Cadiz, who has studied the relationship between longevity and different forms of exercise, andDr. Edwina Brocklesby— nicknamed “Iron Gran” — who is CEO of Silverfit and Britain’s oldest woman to have completed an Ironman triathlon.
In Conversation: What do we know about the gut microbiome in IBD?
Inflammatory bowel disease (IBD) — an umbrella term for conditions including Crohn’s disease and ulcerative colitis — affects millions of people worldwide, sometimes severely affecting their quality of life. How is the gut microbiome of a person with IBD different, and can we use diet to change it and help with disease management? To answer these and other questions, we are in conversation withDr. Marcel de Zoete, associate professor in the Department of Medical Microbiology at UMC Utrecht in The Netherlands, who has studied the gut microbiome in IBD. Also joining us is Zosia Krajewska, who lives with IBD after receiving a diagnosis at age 14.